AMBITION
2015
Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension
In 500 patients with pulmonary arterial hypertension, initial ambrisentan plus tadalafil reduced clinical-failure events compared with monotherapy.
Result
Efficacy: First clinical-failure eventHR 0.5
Below 1 favours ambrisentan plus tadalafil, above 1 favours monotherapy.
- Subtopic
- Combination therapy
- Design
- Double-blind RCT
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Cited in
- ESC/ERS 2022 PH
- Source
- Galiè N, et al. N Engl J Med. 2015;373(9):834-844.doi 10.1056/NEJMoa1413687
Discussion & critique
Established upfront dual combination therapy as the standard initial approach for most patients with PAH.